I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.043 SGD
-10.42%
Market Closed
Updated:
May 8, 2024
IX Biopharma Ltd
Cash from Operating Activities
|
IX Biopharma Ltd
Cash from Operating Activities Peer Comparison
Comparables:
WVE
H02
H
1J5
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Cash from Operating Activities
-S$6.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Cash from Operating Activities
-$19.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Cash from Operating Activities
S$62.7m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Cash from Operating Activities
S$5.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
See Also
What is IX Biopharma Ltd's Cash from Operating Activities?
Cash from Operating Activities
-6.6m
SGD
-6.6m
SGD
Based on the financial report for Dec 31, 2023, IX Biopharma Ltd's Cash from Operating Activities amounts to -6.6m SGD.
What is IX Biopharma Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
9%
9%
Over the last year, the Cash from Operating Activities growth was -1%. The average annual Cash from Operating Activities growth rates for IX Biopharma Ltd have been 10% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
